Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. announced that the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has approved Ustekinumab BS subcutaneous injection [YD], a biosimilar to the reference product, Stelara (Ustekinumab).
The biosimilar Ustekinumab has been developed and manufactured by the company and will be commercialized and marketed in Japan by the company’s exclusive commercial partner, Yoshindo Inc.
Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA).
Biocon Biologics Ltd previously notified the Stock Exchange on Aug 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan, upon regulatory approval.
The provided image outlines an upcoming walk-in interview drive by Ipca Laboratories Ltd. for its…
Based on the image provided, here are all the open job vacancies, along with their…
🚨 HIRING ALERT 🚨 Walk-In Drive for our: 💉 Injectable Unit – Sanand 🏭 OSD…
We’re Hiring | Provis Biolabs Pvt. Ltd. We are looking for talented and motivated professionals…
DEFENCE INSTITUTE OF BIODEFENCE TECHNOLOGIES (DIBT), Mysuru under the aegis of Defence Research & Development…
Accenture Hiring for Pharmacovigilance Services Associate Skill required: Pharmacovigilance Operations - Pharmacovigilance & Drug Safety…